04:57 PM EDT, 08/12/2026 (MT Newswires) -- Allogene Therapeutics ( ALLO ) reported a Q2 loss late Wednesday of $0.13 per diluted share, narrowing from a loss of $0.23 a year earlier.
Collaboration revenue for the three months ended June 30 was $4.6 million.
Cash and cash equivalents as of June 30 were $423.6 million, expected to fund operations into 2029.